Cite
MLA Citation
Igor Puzanov et al.. “Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma.” Journal for immunotherapy of cancer, vol. 1, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100137792946.0x000001